🎉 Big news from China! An innovative mRNA vaccine targeting Epstein-Barr virus positive tumors has just been approved for Phase-I clinical trials by China's Center for Drug Evaluation of the National Medical Products Administration. 🚀
Developed independently by WestGene Biopharma, a biotech company based in Chengdu, Sichuan Province, this groundbreaking injection could be a game-changer in the fight against cancer. Earlier this year, it received the Investigational New Drug approval from the U.S. Food and Drug Administration (FDA), and initial trials in nasopharyngeal carcinoma and lymphoma have already been completed. 🩺✨
Why is this important? Epstein-Barr virus (EBV) is no small villain. Classified as a Group-I carcinogen by the International Agency for Research on Cancer, EBV is the first human oncogenic virus discovered and is linked to over 10 types of malignant tumors, including nasopharyngeal carcinoma, lymphoma, and gastric cancer. 🎯
\"Developing an mRNA tumor therapeutic vaccine is a major breakthrough in the field of mRNA innovative drugs and tumor immunotherapy,\" said Song Xiangrong, co-founder of WestGene Biopharma. 💡
What's next? The company is gearing up to conduct clinical trials across the country to bring this promising mRNA vaccine to patients as soon as possible. This could pave the way for new treatments and offer hope to millions affected by these aggressive cancers. 🙌
Stay tuned for more updates on this exciting development! 🌟
Reference(s):
cgtn.com
